JP2020509052A5 - - Google Patents

Download PDF

Info

Publication number
JP2020509052A5
JP2020509052A5 JP2019547658A JP2019547658A JP2020509052A5 JP 2020509052 A5 JP2020509052 A5 JP 2020509052A5 JP 2019547658 A JP2019547658 A JP 2019547658A JP 2019547658 A JP2019547658 A JP 2019547658A JP 2020509052 A5 JP2020509052 A5 JP 2020509052A5
Authority
JP
Japan
Prior art keywords
dispersible tablet
orally dispersible
lipase
tablet according
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019547658A
Other languages
English (en)
Japanese (ja)
Other versions
JP7208146B2 (ja
JP2020509052A (ja
Filing date
Publication date
Priority claimed from DE102017104472.8A external-priority patent/DE102017104472A1/de
Application filed filed Critical
Publication of JP2020509052A publication Critical patent/JP2020509052A/ja
Publication of JP2020509052A5 publication Critical patent/JP2020509052A5/ja
Priority to JP2022151344A priority Critical patent/JP2022184994A/ja
Application granted granted Critical
Publication of JP7208146B2 publication Critical patent/JP7208146B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019547658A 2017-03-03 2018-03-05 ブルルリパーゼを含有する口腔内分散性錠剤を生産する方法およびブルルリパーゼを含む液体医薬組成物を生産する方法。 Active JP7208146B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022151344A JP2022184994A (ja) 2017-03-03 2022-09-22 ブルルリパーゼを含有する口腔内分散性錠剤、ブルルリパーゼを含む液体医薬組成物を調製する方法および口腔内分散性錠剤を生産するプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102017104472.8 2017-03-03
DE102017104472.8A DE102017104472A1 (de) 2017-03-03 2017-03-03 Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung
PCT/EP2018/055285 WO2018158459A1 (de) 2017-03-03 2018-03-05 Schmelztablette enthaltend burlulipase und daraus hergestellte pharmazeutische zusammensetzung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022151344A Division JP2022184994A (ja) 2017-03-03 2022-09-22 ブルルリパーゼを含有する口腔内分散性錠剤、ブルルリパーゼを含む液体医薬組成物を調製する方法および口腔内分散性錠剤を生産するプロセス

Publications (3)

Publication Number Publication Date
JP2020509052A JP2020509052A (ja) 2020-03-26
JP2020509052A5 true JP2020509052A5 (enExample) 2021-04-15
JP7208146B2 JP7208146B2 (ja) 2023-01-18

Family

ID=61628314

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019547658A Active JP7208146B2 (ja) 2017-03-03 2018-03-05 ブルルリパーゼを含有する口腔内分散性錠剤を生産する方法およびブルルリパーゼを含む液体医薬組成物を生産する方法。
JP2022151344A Pending JP2022184994A (ja) 2017-03-03 2022-09-22 ブルルリパーゼを含有する口腔内分散性錠剤、ブルルリパーゼを含む液体医薬組成物を調製する方法および口腔内分散性錠剤を生産するプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022151344A Pending JP2022184994A (ja) 2017-03-03 2022-09-22 ブルルリパーゼを含有する口腔内分散性錠剤、ブルルリパーゼを含む液体医薬組成物を調製する方法および口腔内分散性錠剤を生産するプロセス

Country Status (9)

Country Link
US (1) US11464834B2 (enExample)
EP (1) EP3525769B1 (enExample)
JP (2) JP7208146B2 (enExample)
CN (1) CN110612098B (enExample)
CA (1) CA3055116C (enExample)
DE (1) DE102017104472A1 (enExample)
ES (1) ES2880602T3 (enExample)
PL (1) PL3525769T3 (enExample)
WO (1) WO2018158459A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017104480A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Wässrige Lösung von Burlulipase umfassend Kalziumionen
JP2023543710A (ja) * 2020-09-17 2023-10-18 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 流動特性を改善するための、高分子量魚ゼラチンに基づく投薬製剤を伴う、界面活性剤の使用
WO2022103634A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Improved use of cannabinoids in the treatment of epilepsy
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
DE102023200788A1 (de) 2023-01-31 2024-08-01 Technische Universität Braunschweig - Körperschaft des öffentlichen Rechts Festes Lyophilisat und Verfahren zur Herstellung

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1642654C3 (de) 1968-01-16 1979-11-29 Centre Europeen De Recherches Mauvernay, C.E.R.M., Riom Verfahren zur mikrobiologischen Herstellung eines stabilen gereinigten Lipase-Präparates und pharmazeutisches Mittel, welches dieses enthält
DE2638088C3 (de) 1976-08-24 1979-06-21 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Verwendung von SuBmolkenpulver
DE69004301T2 (de) 1989-03-08 1994-03-24 Simon Lodewijk Scharpe Mischung zur Behandlung der von exokrinen Insuffizienz der Bauchspeicheldrüse und die Verwendung der genannten Mischung.
JP3593550B2 (ja) 1991-07-01 2004-11-24 ノルトマルク アルツナイミッテル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 医薬品製造のためのリパーゼの使用
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
WO2000078292A1 (en) 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
US6588180B2 (en) 2001-02-02 2003-07-08 R. P. Scherer Technologies, Inc. Constricted neck blister pack and apparatus and method for making the same
AU2003233118B8 (en) 2002-05-07 2009-07-30 Ferring Bv Desmopressin in an orodispersible dosage form
CN1394607A (zh) 2002-08-07 2003-02-05 王登之 治疗心绞痛的黄杨宁口腔崩解片及其制备方法
DE602005009677D1 (de) 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
HUE031245T2 (en) 2004-10-14 2017-06-28 Lilly Co Eli Preparations containing lipase, protease and amylase for the treatment of pancreatic insufficiency
US8802145B2 (en) 2004-10-28 2014-08-12 Pantec Ag Highly porous, fast-disintegrating solid dosage form and its way of manufacturing comprising the preparation of a powder and a freezedrying step
WO2010025126A1 (en) 2008-08-26 2010-03-04 Cystic Fibrosis Foundation Therapeutics, Inc. Rapidly disintegrating tablets comprising lipase, amylase, and protease
DE102009006594A1 (de) 2009-01-29 2010-08-05 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutisches Präparat
EP2786761A1 (de) * 2009-01-29 2014-10-08 Nordmark Arzneimittel GmbH & Co.KG Pharmazeutisches Präparat
WO2014166994A1 (en) 2013-04-09 2014-10-16 Danmarks Tekniske Universitet Nano-microdelivery systems for oral delivery of an active ingredient
CN104109662B (zh) 2014-06-23 2017-03-01 华中科技大学 一种固定化的洋葱伯克霍尔德菌脂肪酶及其制备方法
DE102015114857A1 (de) 2015-09-04 2017-03-09 Nordmark Arzneimittel Gmbh & Co. Kg Getränk, enthaltend eine pharmazeutische Zusammensetzung

Similar Documents

Publication Publication Date Title
JP2020509052A5 (enExample)
AU2011227446B2 (en) Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
EP3154529B1 (en) Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
KR101908748B1 (ko) 구강내 붕괴정
JP2010070576A (ja) 速溶解性錠剤
JP5517327B2 (ja) 口腔内崩壊錠用組成物
CN109996542A (zh) 包含二胺衍生物的口腔崩解片
WO2010147169A1 (ja) 溶出性の改善された医薬組成物
CN110612098B (zh) 含有伯鲁酶的口腔分散片和由此生产的药物组合物
JP7361833B2 (ja) 2-[3-シアノ-4-(2-メチルプロポキシ)フェニル]-4-メチルチアゾール-5-カルボン酸の口腔内崩壊錠
KR20150118160A (ko) 장용정
CN104706604A (zh) 一种吡仑帕奈冻干口崩片及其制备方法
WO2016088816A1 (ja) 酢酸亜鉛水和物錠及びその製造方法
KR101813065B1 (ko) 알긴산 및/또는 알긴산염을 포함하는 고형 제제
KR102431738B1 (ko) 초고속 붕해 정제 및 그 제조 방법
TW201717916A (zh) 超高速崩解錠劑及其製造方法
KR100855189B1 (ko) 구강 속붕해성 정제
TWI606847B (zh) 口腔內崩解錠
JP6498158B2 (ja) 口腔内崩壊錠
JP6443891B2 (ja) 徐放性製剤
EP2793856B1 (en) Orally-disintegrating formulations of flurbiprofen
KR20250052666A (ko) 고용량 판크레아틴 직접타정용 약제학적 조성물, 및 이에 의해 제조된 장용성 정제
Umasankar et al. Fast dissolving tablet–review article
EP2609910A1 (en) Formulations of eprotirome
KR20180099450A (ko) 알긴산 및/또는 알긴산염을 포함하는 고형 제제